Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00563290
Other study ID # NCI-2009-00226
Secondary ID NCI-2009-00226CD
Status Completed
Phase Phase 2
First received November 22, 2007
Last updated May 21, 2015
Start date November 2007
Est. completion date October 2014

Study information

Verified date March 2015
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This phase II trial is studying how well dasatinib works in treating patients with unresectable or metastatic squamous cell skin cancer or RAI Stage 0-I chronic lymphocytic leukemia. Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.


Description:

PRIMARY OBJECTIVES:

I. Determine the objective response rate (complete response and partial response) in patients with unresectable or metastatic squamous cell carcinoma of the skin or RAI stage 0-I chronic lymphocytic leukemia receiving dasatinib.

SECONDARY OBJECTIVES:

I. Determine the progression-free survival of patients receiving this drug. II. Evaluate tumor for presence of total EphA2 and both total and active Src and FAK by immunohistochemistry (IHC) pre-treatment with dasatinib.

III. Evaluate tumor for presence of cyclooxygenase-2 by IHC pre-treatment with dasatinib.

OUTLINE: Patients are assigned to 1 of 2 treatment arms.

ARM I: Patients receive 100 mg dasatinib orally (PO) twice daily (BID) on days 1-28.

ARM II (PATIENTS ENROLLED AFTER 11/18/08): Patients receive 70 mg dasatinib PO BID on days 1-28.

In both arms, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Pre-therapy tumor biopsy specimens are collected to detect total and phosphorylated Src and FAK, total EphA2, and cyclooxygenase-2 by immunohistochemistry.

After completion of study treatment, patients are followed up monthly for up to 12 weeks.


Recruitment information / eligibility

Status Completed
Enrollment 7
Est. completion date October 2014
Est. primary completion date April 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Diagnosis of 1 of the following

- Histologically or cytologically confirmed squamous cell carcinoma of the skin

- Unresectable or metastatic disease

- Squamous cell histology represents = 50% of the biopsy specimen

- May or may not be related to autologous or allogeneic organ transplantation

- Chronic lymphocytic leukemia (CLL)

- RAI stage 0-I

- Stable disease

- Patients with basalosquamous cell disease (basal cell with squamous differentiation) are eligible

- Measurable disease, defined as at least 1 unidimensionally measurable lesion = 20 mm by conventional techniques or = 10 mm by spiral CT scan

- Must be willing to undergo a pre-treatment tumor biopsy

- Brain metastases are allowed provided the following are true:

- Received definitive therapy consisting of external beam radiation therapy, gamma knife therapy, or surgical resection resulting in clinically stable disease

- Lesions are under control for at least 4 weeks after completion of definitive therapy, as measured by repeat MRI or CT scans

- No requirement for dexamethasone

- ECOG performance status 0-1 OR Karnofsky 60-100%

- Life expectancy > 6 months

- WBC = 3,000/mm^3

- Absolute neutrophil count = 1,500/mm^3

- Platelets = 100,000/mm^3

- Total bilirubin = 1.5 times upper limit of normal(ULN)

- AST/ALT = 2.5 times ULN

- Potassium 3.5 - 5.1 mmol/L

- Calcium > lower limit of normal

- Creatinine = 1.5 times ULN OR creatinine clearance = 60 mL/min

- No known HIV 1 or HIV 2 positivity

- No known hepatitis C or hepatitis B positivity

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No history of allergic reactions attributed to compounds of similar chemical or biological composition to dasatinib

- No QTc prolongation, defined as a QTc interval of = 480 msecs or other significant ECG abnormality

- No condition that impairs the ability to swallow and retain dasatinib tablets (e.g., gastrointestinal tract disease resulting in an inability to take oral medication, requirement for IV alimentation, prior surgical procedure affecting absorption, or active peptic ulcer disease)

- No clinically significant cardiovascular disease including the following:

- Myocardial infarction within 6 months

- Uncontrolled angina within 3 months

- Diagnosed or suspected congenital long QT syndrome

- Any history of clinically significant ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, or Torsades de Pointe)

- Any history of second or third degree heart block (may be eligible if the subject currently has a pacemaker)

- Heart rate consistently < 50 beats/minute on pre-entry ECG

- Uncontrolled hypertension

- Ejection fraction < 45% by transthoracic echo

- No uncontrolled intercurrent illness including, but not limited to, the following:

- Ongoing or active infection requiring intravenous antibiotics

- History of significant bleeding disorder, including congenital (von Willebrand's disease) or acquired (anti-factor VIII antibodies) disorders

- Psychiatric illness or social situations that would limit compliance with study requirements

- No prior malignancy except for adequately treated basal cell cancer, carcinoma in situ of the cervix, or other cancer for which the patient has been disease free for 3 years

- No gastro-esophageal reflux disease dependent on proton pump inhibitors, H2 blockers, or antacids

- Recovered from prior therapy

- No more than 1 prior therapy with a monoclonal antibody

- No more than 1 prior chemotherapy regimen

- No prior tyrosine kinase inhibitor therapy

- Prior erlotinib hydrochloride allowed

- More than 2 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C) and recovered

- At least 4 weeks since prior radiotherapy

- Measurable disease must be outside the radiotherapy port

- At least 2 weeks since prior topical therapy

- At least 4 weeks since prior surgery requiring general anesthesia and intubation

- At least 120 days (4 months) since prior amiodarone

- At least 7 days since prior and no concurrent anti-thrombotic and/or platelet agents (e.g., warfarin, heparin, low molecular weight heparin, aspirin [full dose and 81 mg dose] and/or ibuprofen)

- At least 7 days since prior and no concurrent agents with pro-arrhythmic potential

- More than 7 days or 5 half lives, whichever is greater, since prior and no concurrent agents or substances that induce or inhibit CYP3A4

- No concurrent bisphosphonate therapy for the first 8 weeks of dasatinib treatment

- No other concurrent investigational agents

- No concurrent combination antiretroviral therapy for HIV-positive patients

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
dasatinib
Given PO
Other:
laboratory biomarker analysis
Correlative studies

Locations

Country Name City State
United States Cincinnati Children's Hospital Medical Center Cincinnati Ohio
United States Ohio State University Medical Center Columbus Ohio
United States M D Anderson Cancer Center Houston Texas

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Objective Response Rate (Complete Response and Partial Response) Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Every 2 courses during treatment, assessed up to 12 weeks after completion of treatment No
Secondary Progression-free Survival Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions Time from start of treatment to time of progression, assessed up to 12 weeks No
Secondary Presence of Total EphA2 and Both Total and Active Src and FAK by Immunohistochemistry (IHC) Performed per standard protocols by the Pathology Department. At baseline No
Secondary COX-2 Presence by IHC Performed per standard protocols by the Pathology Department. Samples will be obtained pre-therapy. Determination of the COX-2 tumor status on this trial will develop the beginnings of a data base upon which future therapy may be designed. At baseline No
See also
  Status Clinical Trial Phase
Completed NCT01093586 - Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Phase 2
Terminated NCT00387426 - Sunitinib in Treating Patients With Idiopathic Myelofibrosis Phase 2
Terminated NCT00377104 - Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Phase 1
Completed NCT01588015 - Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant Phase 1
Completed NCT01441882 - Dasatinib in Treating Patients With Chronic Lymphocytic Leukemia Phase 2
Terminated NCT00288067 - Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma Phase 1/Phase 2
Completed NCT00098670 - Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia Phase 2
Completed NCT02100423 - Curcumin and Cholecalciferol in Treating Patients With Previously Untreated Stage 0-II Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Phase 2
Terminated NCT00303966 - Sorafenib in Treating Patients With Relapsed Chronic Lymphocytic Leukemia Phase 2
Active, not recruiting NCT01351896 - Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Phase 2
Completed NCT00112593 - Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer N/A
Completed NCT01024010 - Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Phase 2
Completed NCT01789255 - Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies Phase 2
Active, not recruiting NCT01361711 - Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia Phase 2
Completed NCT00918723 - Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Phase 1/Phase 2
Completed NCT00003620 - Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia Phase 2
Terminated NCT02309515 - Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell Lymphocytosis Phase 2
Active, not recruiting NCT02213913 - Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas Phase 1/Phase 2
Completed NCT01269385 - Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia Phase 1/Phase 2
Completed NCT01649791 - Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia N/A